HCPCS Codes Similar to Q2058

HCPCS Codes Similar to “Q2058” Code.
Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

C9301 Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20250401 Code effective date: 20250701 TXT \| PDF \| XML \| JSON	C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210101 Code effective date: 20210401 TXT \| PDF \| XML \| JSON
Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210401 Code effective date: 20210401 TXT \| PDF \| XML \| JSON	C9076 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210701 Code effective date: 20211001 TXT \| PDF \| XML \| JSON
Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20180401 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20211001 TXT \| PDF \| XML \| JSON
C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20220701 Code effective date: 20221001 TXT \| PDF \| XML \| JSON	Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20221001 Code effective date: 20221001 TXT \| PDF \| XML \| JSON
Q2057 Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20250401 Code effective date: 20250401 TXT \| PDF \| XML \| JSON	C9081 Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20220101 TXT \| PDF \| XML \| JSON
Q2040 Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion Code added date: 20180101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20190101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON
Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20220101 Code effective date: 20240404 TXT \| PDF \| XML \| JSON	Q2043 Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion Code added date: 20110701 Code effective date: 20110701 TXT \| PDF \| XML \| JSON